Literature DB >> 33475231

Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing.

Nicky Best1, Robert G Price2, Isabelle J Pouliquen1, Oliver N Keene1.   

Abstract

Assessment of efficacy in important subgroups - such as those defined by sex, age, race and region - in confirmatory trials is typically performed using separate analysis of the specific subgroup. This ignores relevant information from the complementary subgroup. Bayesian dynamic borrowing uses an informative prior based on analysis of the complementary subgroup and a weak prior distribution centred on a mean of zero to construct a robust mixture prior. This combination of priors allows for dynamic borrowing of prior information; the analysis learns how much of the complementary subgroup prior information to borrow based on the consistency between the subgroup of interest and the complementary subgroup. A tipping point analysis can be carried out to identify how much prior weight needs to be placed on the complementary subgroup component of the robust mixture prior to establish efficacy in the subgroup of interest. An attractive feature of the tipping point analysis is that it enables the evidence from the source subgroup, the evidence from the target subgroup, and the combined evidence to be displayed alongside each other. This method is illustrated with an example trial in severe asthma where efficacy in the adolescent subgroup was assessed using a mixture prior combining an informative prior from the adult data in the same trial with a non-informative prior.
© 2021 The Authors. Pharmaceutical Statistics published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bayesian; borrowing; confirmatory; exacerbation; paediatric; subgroup

Year:  2021        PMID: 33475231     DOI: 10.1002/pst.2093

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  2 in total

Review 1.  Reverse-Bayes methods for evidence assessment and research synthesis.

Authors:  Leonhard Held; Robert Matthews; Manuela Ott; Samuel Pawel
Journal:  Res Synth Methods       Date:  2021-12-30       Impact factor: 9.308

2.  Frequentist rules for regulatory approval of subgroups in phase III trials: A fresh look at an old problem.

Authors:  K Edgar; D Jackson; K Rhodes; T Duffy; C-F Burman; L D Sharples
Journal:  Stat Methods Med Res       Date:  2021-06-02       Impact factor: 3.021

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.